Non-Small Cell Lung Cancer (NSCLC) Market – Trends Forecast Till 2030

Market Snapshot

Market Overview

The global Non-Small Cell Lung Cancer (NSCLC) market size was estimated at USD 15.1 billion in 2023 and is projected to reach USD 28.3 billion in 2030 at a CAGR of 9.40% during the forecast period 2023-2030.

Non-small cell lung cancer is a type of lung cancer in which malignant tumor cells form in the lungs. It includes a group of different diseases that behave similarly, such as squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Adenocarcinoma is a type of non-small cell lung cancer that occurs more often in women than men and in young people than in the elderly. It is more common in people who have smoked and who have been exposed to polluted air more than those who smoke regularly. Squamous cell carcinoma is another common type of non-small cell lung cancer that is mostly caused by smoking. It occurs mostly in the middle part of the lungs, which is near the main airways. Large cell carcinoma can be more difficult to treat because it can be found anywhere in the lung and tends to spread more quickly than the other two.

The increasing number of patients suffering from non-small cell lung cancer worldwide is one of the major drivers for the growth of the market. This is mainly because there are more and more people in the world with unhealthy habits such as smoking, tobacco and alcohol consumption, high doses of nutritional supplements and sedentary lifestyles. In addition, the increase in air pollution is also one of the main factors affecting the increase in the number of sick people. According to statistics published by the World Health Organization (WHO) from February 2022, 2.2 million patients were diagnosed with lung cancer in 2020, and non-small cell lung cancer accounted for nearly 85% of all lung cancer patients. Thus, the availability of a large patient population and the increase in the number of patients with non-small cell lung cancer to treat patients has resulted in a high demand for the therapy.

The overall impact of COVID-19 pandemic remained negative for key players in the non-small lung cancer treatment market. The decline is due to decrease in number of patients diagnosed with non-small cell lung cancer in 2020 owing to lockdown restrictions along with disruption of supply chain during pandemic resulting in shortage of therapeutics.

Delvens Industry Expert's Standpoint

The pandemic had a considerable impact on businesses globally, with nations like India and China bearing the brunt of the virus's outbreak. Non-small cell lung cancer accounts for 80-85% of all lung cancer cases worldwide, and this significant share of non-small cell lung cancer has led most of the major market leaders to focus on continuous innovation and increasing the effectiveness of advanced medicines and existing treatment methods. This is also due to the position of lung cancer as one of the most common cancers in the world and its impact on a significant number of deaths worldwide. Increasing diagnosis of non-small cell lung cancer and increased awareness of developed and developing markets in developed countries are also fueling the growth of the non-small cell lung cancer therapeutics market. This along with increasing R&D investments by key players and inclusion of non-small cell cancer drugs among key market players is also fueling market growth globally. These factors have led to the expansion of the market and increased demand for Non-Small Cell Lung Cancer (NSCLC) solutions.

Market Portfolio

Key Findings

• The type segment is further fragmented into Adenocarcinoma, Squamous Cell Carcinoma, Large Cell Carcinoma and Others. The adenocarcinoma segment is expected to account for a larger market size during the forecast period due to the number of patients with adenocarcinoma and the wide range of drugs used for this indication. The squamous cell carcinoma segment is expected to register a higher CAGR during the forecast period. For example, according to the American Gastroenterological Association, there were approximately 604,100 new cases of esophageal cancer in 2020.

• The treatment segment is further bifurcated into Chemotherapy, Targeted Therapy and Immunotherapy. The targeted therapy is the largest market during the forecast period owing to distinct clinical benefits offered by this therapy such as minimal side effects along with availability of number of targeted therapeutics. In addition, rise in number of people turning to targeted therapy as a form of treatment for cancer, and targeted therapy is successful in upto 80% of cases.

• The distribution channel segment is further bifurcated into Hospital Pharmacy, Drug Store and Retail Pharmacy and Online Pharmacy. Hospital pharmacy to account for a larger market size during the forecast period. The dominance is due to increase in number of hospitalizations of patients suffering with NSCLC and presence of skilled professionals within these settings.
   
• The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America is estimated to account for the largest market share during the forecast period. In North America, owing to well-established healthcare infrastructure, higher awareness among people regarding early diagnosis of cancer, presence of favorable reimbursement policies and strong presence of key players in this region.

Regional Analysis

North America to Dominate the Market

• North America is estimated to account for the largest market share during the forecast period. In North America, owing to well-established healthcare infrastructure, higher awareness among people regarding early diagnosis of cancer, presence of favorable reimbursement policies.
   
• Moreover, the strong presence of key players in this region is expected to boost the North American market growth.

Competitive Landscape

• Agennix AG
• Astellas Pharma Inc.
• AstraZeneca
• Bayer AG
• Boehringer Ingelheim
• Bristol-Myers Squibb Company
• Celgene Corporation
• Clovis Oncology
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Genentech Inc.
• GlaxoSmithKline plc.
• GSK plc
• Johnson & Johnson Private Limited
• Lupin
• Merck & Co., Inc.
• Millennium Pharmaceuticals, Inc. (Takeda)
• Mylan N.V.
• Novartis AG
• Pfizer Inc.
• Roche Holding AG
• Sanofi
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.

Recent Developments

• In August 2022, the Food and Drug Administration granted regular approval to capmatinib (Tabrecta, Novartis Pharmaceuticals Corp.) for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation leading to mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by an FDA-approved test.
   
• In March 2022, Regeneron and BioNTech expanded their collaboration agreement for the development of Libtayo and FixVac (cemiplimab) Combination to treat advanced NSCLC.

Reasons to Acquire

• Increase your understanding of the market for identifying the most suitable strategies and decisions based on sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors.
   
• Gain authentic and granular data access for the Non-Small Cell Lung Cancer (NSCLC) Market to understand the trends and the factors involved in changing market situations.
   
• Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.
   
• In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.

Report Scope